Cantel Medical (CMN) Tops Q4 EPS by 6c

October 7, 2008 8:37 AM EDT

Cantel Medical (NYSE: CMN) reports Q4 EPS of $0.16, 6 cents better than estimates. Sales were $64,281,000 for the fourth quarter vs. $62.51 million consensus.

Andrew Krakauer, Cantel's President, stated, "We are pleased to have delivered our strongest quarterly performance of the past three years despite unprecedented cost increases impacting most of our business units. Our success was aided by solid sales growth in all businesses except for a decline in low margin dialysate concentrate shipments in our Dialysis segment. During the quarter, we achieved over 10% revenue growth exclusive of Dialysis."

Krakauer continued, "In fiscal 2009 we anticipate benefiting from ongoing cost improvement programs, our own price increases and reduced interest expense. Most importantly, we expect success from new product introductions and from our 2008 investments in sales and marketing."

Cantel Medical Corporation is a provider of infection prevention and control products in the healthcare market. [SM]

Related Categories

Earnings

Stocks Mentioned

Related Entities

• Raising Prices

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?